Pierre Fabre revealed the data of phase 3 trial known as BEACON. This study used encorfenib (BRAF inhibitor), binimetinib (MEK inhibitor) and cetuximab (anti-EGFR antibody) for the treatment of BRAF V600E-mutant metastatic colorectal cancer (mCRC), in subjects who have already received one or two line of therapy as per the inclusion criteria of the study protocol.
The revealed data showed that this combination has a statistically significant development in median overall survival(OS), extending it by twice the time which is nine months compared to 4.3 months in the control group treated with cetuximab plus irinotecan-containing regimens. The triplet also demonstrated a developed overall response (OS) rate of 26% in comparison to 2% for the encorafenib triplet and control group respectively, while median progression-free survival (PFS) stood at 4.3 months versus 1.5 months.
Additionally, analysis done at interval demonstrated that the combination of encorafenib and cetuximab, known as the encorafenib doublet, improved median OS by 8.4 months with an ambitious response rate (ORR) of 20% compared to 5.4 months and 2% in the control group.
Both set of combinations i.e., doublet and triplet were well-tolerated with none adverse events and were found to be constant in regards with the safety profiles.
Clinical Research Newsletter
Mr Vinod Arora, Principal Advisor, IGMPI
Placement testimonials: Our alumni are working with Fortune 500 and global Pharmaceutical, Food and healthcare giants like